The systemic inflammatory response syndrome treatment market is estimated to grow with a moderate CAGR during the forecast period, i.e., 2021-2029. Increasing incidences of systemic inflammatory response syndrome disease due to lifestyle changes, raising awareness about the disease, and the availability of treatments is expected to fuel this market's progress. The growth of the market can also be attributed to the rising prevalence of SIRS disease amongst individuals on a global level. The U.S. National Library of Medicine published an article which indicated that, out of 372,844,465 visits to the emergency department from 2007 to 2010, an estimated 17.8% ED visitors had SIRS, i.e., 16.6 million adult ED visits with SIRS per year.
On the basis of indication type, the market is segmented into meningitis, urinary tract infection (UTI), pneumonia, hemorrhage, autoimmune diseases, and others. Out of which, revenue from the treatment of urinary tract infection holds the highest share as dehydration, high consumption of birth control pills, menopause, and frequent involvement in sexual activities are leading causes of UTI. Females are more prone to UTI as they have a shorter urethra than males as a result, which shortens the distance for bacteria to reach the bladder.
On the basis of end-users, the market is segmented into hospital & ambulatory surgical centers, specialty clinics, and others. Specialty clinics segment hold the highest share of the market as a considerable portion of the population with disease on a global level tend to choose healthcare facilities specializing in specific treatment.
Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa region. The market in the Asia Pacific is predicted to grow at the highest CAGR over the forecast period owing to the increasing awareness about the disease and the need to develop innovative inflammatory disease treatment solutions in the region. In 2021, the market in North America is evaluated to occupy the largest share in terms of revenue followed by Europe.
The global SIRS treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the global SIRS treatment market includes the following segments:
FREQUENTLY ASKED QUESTIONS
Increasing incidence of bowel disorders such as systemic inflammatory response syndrome due to lifestyle changes and increasing awareness about the disease are the key growth drivers.
The market is anticipated to attain a moderate CAGR over the forecast period, i.e., 2021-2029.
High cost of treatment and delay in diagnosis are estimated to hamper market growth.
The market in Asia Pacific region will provide ample growth opportunities owing to the increasing awareness about systemic inflammatory response syndrome.
The major players dominating the SIRS treatment market are Endacea, Inc., Adrenomed AG, GlaxoSmithKline plc, Asahi Kasei Corporation, Cardinal Health, among others.
The company profiles are selected on the basis of revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by indication type, end user and region.
With respect to application, the specialty clinics segment is anticipated to hold the largest market share owing to the growing preference among individuals for specialty treatment facilities for diseases.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization